Medical and Health Science Journal

  Previous Article | Back to Volume | Next Article
  Abstract | References | Citation | Download | Preview | Statistics
Volume 16
Issue 2
Online publication date 2015-07-27
Title Role of morphogenetic proteins - FGF-23, soluble alfa-Klotho and glycoprotein sclerostin in vascular calcification in patients with chronic kidney disease
Author Ludmila Milovanova, Daria Kudriavtseva, Yuriy Milovanov, Sergey Moiseev
The aim of the study was to investigate the relationship between FGF-23, Klotho, sclerostin serum level changes and diffuse arterial stiffness, calcification intensity and myocardial remodelling in patients with different stages of Chronic Kidney Disease (CKD). 

The control group consisted of 15 volunteers the same average age and sex. Serum FGF-23 levels (Human FGF-23 ELISA kit using monoclonal antibodies to the full FGF-23 molecule), Klotho (Human alpha-Kl ELISA using anti-Klotho antibodies) and sclerostin ( Human sclerostin ELISA kit) were applied in these patients. Blood pressure (BP) was measured to all study patients. Echocardiography was performed to patients with arterial hypertension and left ventricular mass index (LVMI) was calculated. The state of blood flow in the heart and large vessels (Doppler ultrasound Echocardiography), pulse wave velocity (Sphigmokor), calcifications presence (echocardiography, radiography of abdominal aorta by Kauppila method) and vascular wall functional ability (augmentation indices by Sphigmokor) were studied. Among 49 hypertensive patients in 27 (55.1 %) from them it was able to maintain target BP-120/80-140/80 mm Hg., the remaining 22 (44.9%) patients took antihypertensive medications irregularly. At the start of screening they had been remained hypertensive (BP 150/90-165/100 mm Hg). 

Our study demonstrated that serum levels of Klotho, FGF-23, sclerostin are early markers of cardiovascular events in CKD. It was found the clear link between increased serum FGF-23 and decreased Klotho and sclerostin as increasing CKD severity, and diffuse arterial stiffness and calcification, myocardial remodelling independent of traditional risk factors. To the final determination of the sclerostin role in CKD more exactly further researches are required.

Couser WG., Remuzzi G., Mendis S., Tonelli M., 2011. "The contribution of chronic kidney disease to the global burden of major noncommunicable diseases", Kidney Int., Vol.80(12): pp.1258-1270,
Devereux R.B., 1990. "The value of noninvasive measurements in hypertension", J. Am. Med. Assoc., Vol.264(2), pp.2798-9,
Gutierrez O.M., Januzzi J.L., Isacova T. et al., 2009. "Fibroblast growth factor-23 and left ventricular hypertrophy in chronic kidney disease", Circulation, Vol.119(9), pp.2545-2552,
Hu M.C., Shi M., Zhang J. et al., 2011. "Klotho deficiency causes vascular calcification in chronic kidney disease", Am. J. Soc. Nephrol., Vol.22(1), pp.124-136,
Isha Agarwal, Noriko Ide, Joachim H. Ix et al., 2014. "Fibroblast Growth Factor-23 and Cardiac Structure and Function", J Am Heart Assoc., Vol.3(1), pp.132-135,
Jean G., Terrat J.C., Vanel T. et al., 2009. "High levels of serum Fibroblast Growth Factors (FGF)-23 are associated with increased mortality in long haemodialysis patients", Nephrol. Dial. Transplant., Vol.24, pp.2792-2796,
Julia J. Scialla, Huiliang Xie, Mahboob Rahman et al., 2014. "Fibroblast Growth Factor-23 and Cardiovascular Events in CKD", J Am Soc Nephrol., Vol.25(2), pp.349-360,
KDIGO, 2009. "Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evalution, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)", Kidney Int., Vol.76 (Suppl.113), pp.1-130
Kuo-Cheng Lu, Chia-Chao Wu, Jen-Fen Yen et al., 2014. "Vascular calcification and Renal Bone Disorders", Scientific World Journal, Published online 2014 Jul 17. doi: 10.1155/2014/637065,
Kuro-o M., 2009. "Klotho in chronic kidney disease - What's new?", Nephrology Dialysis Transplant, Vol.24(6), pp.1705-1708,
Ming Chang Hu, Makoto Kuro-o, Orson W. Moe, 2013a. "Klotho and Chronic Kidney Disease", Contrib Nephrol., Vol.180, pp.47-63,
Ming Chang Hu, Makoto Kuro-o, Orson W. Moe, 2013b. "Renal and extra-renal actions of Klotho", Semin Nephrol., Vol.33(2), pp.118-129,
Milovanova L.Y., Milovanov Y.S., Kozlovskaya L.V., 2013. "Nephro-cardioprotective role of the circulating forms of the KLOTHO protein in chronic kidney disease", Clinical Nephrology, Vol.3: pp.7-10
Milovanova L., Milovanov Y., Plotnikova A., 2012. "Phosphorus and Calcium Metabolism Disorders Assosiated with Chronic Kidney Disease Stage III-IV (Systematic Rewiew and Meta-Analysis)", In: Chronic Kidney Disease and renal Transplantation. Croatia, INTECH, pp.95-118
Román-García P., Carrillo-López N., Fernández-Martín J.L. et al., 2010. "High phosphorus diet induces vascular calcification, a related decrease in bone mass and changes in the aortic gene expression", Bone, Vol.46(1), pp.121-128,
Silverman S.L., 2010. "Sclerostin", Journal of Osteoporosis, Vol.3, pp.94-99,
Zhu D., Mackenzie NCW, Millán J.L., Farquharson C., MacRae V.E., 2011. "The appearance and modulation of osteocyte marker expression during calcification of vascular smooth muscle cells", PLoS ONE, Vol.6(5), pp.67-71,
Keywords Chronic kidney disease, ectopic calcification, fibroblast growth factor-23, left ventricular hypertrophy, sсlerostin, soluble alpha-Klotho
Pages 26-37
Download Full PDF Download
  Previous Article | Back to Volume | Next Article
Search in articles
Journal Published articles
MHSJ 940
Journal Hits
MHSJ 2566869
Journal Downloads
MHSJ 17488
Total users online -